<p>The race to develop a <a href="https://www.deccanherald.com/tag/coronavirus" target="_blank">Covid-19</a> vaccine is on, and the market could possibly be worth $6 billion in India in terms of sales for the coming three years, with the public exchequer expected to foot about $2 billion to immunise half the population required to reach herd-immunity levels, according to a <a href="https://www.livemint.com/news/india/covid-19-vaccine-market-to-be-worth-6-billion-in-india-bernstein-11598523909729.html" target="_blank">report </a>by <em>Mint </em>quoting international brokerage Sanford C. Bernstein.</p>.<p>"If the government chose to vaccinate the entire population, they would need to set aside an additional $6 billion. This would imply an almost 100 percent increase to the current Central Government Healthcare budget," Bernstein analyst Nithya Balasubramanian is quoted as saying in the report.</p>.<p><a href="https://www.deccanherald.com/national/coronavirus-news-live-updates-india-world-coronavirus-vaccine-karnataka-maharashtra-tamil-nadu-delhi-kerala-gujarat-west-bengal-bangalore-mumbai-new-delhi-chennai-kolkata-cases-deaths-recoveries-876781.html" target="_blank"><strong>For latest updates and live news on coronavirus, click here</strong></a></p>.<p>Assuming that the government would immunise approximately 30% of India’s population, Balasubramanian priced the vaccine at $3 (Rs 222 approximately) per dose for government procurement. The remainder of the population will have to buy the vaccine privately, which would cost around $6.</p>.<p>Gavi, a member of the Vaccine Alliance and Bill & Melinda Gates Foundation with Serum Institute of India, has approved of the estimated vaccine price.</p>.<p>"The throughput can, of course, be increased but cold chain storage facilities and manpower (ASHA workers, ANMs and other last-mile delivery support workers) will prove to be bottlenecks. Having worked on public-private-partnership models in my earlier life, I can say with confidence that manpower will be the largest bottleneck to faster implementation," Balasubramanian, a former Cipla executive, is quoted as saying in the report.</p>.<p>According to the report, covering 340 million people with two doses each would take the government about three years.</p>.<p>($1 = Rs 73.83)</p>
<p>The race to develop a <a href="https://www.deccanherald.com/tag/coronavirus" target="_blank">Covid-19</a> vaccine is on, and the market could possibly be worth $6 billion in India in terms of sales for the coming three years, with the public exchequer expected to foot about $2 billion to immunise half the population required to reach herd-immunity levels, according to a <a href="https://www.livemint.com/news/india/covid-19-vaccine-market-to-be-worth-6-billion-in-india-bernstein-11598523909729.html" target="_blank">report </a>by <em>Mint </em>quoting international brokerage Sanford C. Bernstein.</p>.<p>"If the government chose to vaccinate the entire population, they would need to set aside an additional $6 billion. This would imply an almost 100 percent increase to the current Central Government Healthcare budget," Bernstein analyst Nithya Balasubramanian is quoted as saying in the report.</p>.<p><a href="https://www.deccanherald.com/national/coronavirus-news-live-updates-india-world-coronavirus-vaccine-karnataka-maharashtra-tamil-nadu-delhi-kerala-gujarat-west-bengal-bangalore-mumbai-new-delhi-chennai-kolkata-cases-deaths-recoveries-876781.html" target="_blank"><strong>For latest updates and live news on coronavirus, click here</strong></a></p>.<p>Assuming that the government would immunise approximately 30% of India’s population, Balasubramanian priced the vaccine at $3 (Rs 222 approximately) per dose for government procurement. The remainder of the population will have to buy the vaccine privately, which would cost around $6.</p>.<p>Gavi, a member of the Vaccine Alliance and Bill & Melinda Gates Foundation with Serum Institute of India, has approved of the estimated vaccine price.</p>.<p>"The throughput can, of course, be increased but cold chain storage facilities and manpower (ASHA workers, ANMs and other last-mile delivery support workers) will prove to be bottlenecks. Having worked on public-private-partnership models in my earlier life, I can say with confidence that manpower will be the largest bottleneck to faster implementation," Balasubramanian, a former Cipla executive, is quoted as saying in the report.</p>.<p>According to the report, covering 340 million people with two doses each would take the government about three years.</p>.<p>($1 = Rs 73.83)</p>